This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TAL6 scFv to FasL. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TAL6 as well as the biological activity of FasL. This antibody-cytokine fusion protein is highly effective in in vitro killing of human TAG-72+ Jurkat-Ras tumor cells with a 500-fold greater cytotoxicity as compared to soluble FasL (sFasL). ScFv-FasLext with a strong cytotoxicity against sensitive human tumor targets may be useful as effective chemotherapeutic agents. This immunocytokine was designed for treating carcinomas of the breast, colon, lung, and ovary.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-3551z | Mouse Anti-TM4SF1 Recombinant Antibody (clone 41H4) | FC, ICC, IHC | Mouse IgG1 |
VS-0723-WK10 | Human Anti-TM4SF1 Recombinant Antibody (VS-0723-WK10) | FC | Human IgG1 |
There are currently no Customer reviews or questions for ACFP-SH151. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.